share_log

摩根大通证券公司:维持BioCryst Pharma(BCRX.US)评级,由优于大市调整至优于大市评级, 目标价由14.00美元调整至15.00美元。

Zhitong Finance ·  May 7 11:34

摩根大通证券公司:维持BioCryst Pharma(BCRX.US)评级,由优于大市调整至优于大市评级, 目标价由14.00美元调整至15.00美元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment